Factors affecting COVID-19 disease severity in breast cancer patients: Single-Center experience COVID-19 Breast Cancer
Article Sidebar
Main Article Content
Abstract
Objective: Coronavirus disease-19 (COVID-19) is one of the large-scale pandemics affecting the whole World. Breast cancer is the most common cancer in women. This study aims to examine the factors that may be effective on COVID-19 disease severity in breast cancer patients.
Material and Methods: This study was carried out as a single-center and retrospective study with a total of 65 patients with a pathological diagnosis of breast cancer who were hospitalized between April 2020 and June 2021. The patients were divided into two groups, mild and severe. 35 patients were in the mild group and 30 patients were in the severe group. Patients with oxygen saturation below 93 percent, needing non-invasive or invasive mechanical ventilation, acute respiratory distress syndrome, shock, and multiple organ failure were included in the severe group.
Results: A total of 17 parameters that may affect disease severity were analyzed. As a result of the univariate analysis performed to evaluate the potential factors that may affect the severity of the disease, statistically, significant differences were found: the patient had diabetes mellitus (P=0.050), the neutrophil count increased during hospitalization (P=0.002), the lymphocyte count decreased at admission (P). =0.001), high d-dimer level during hospitalization (P=0.007), lymphocyte to monocyte ratio above 2.55 (P=0.016).
Conclusion: As a result, the presence of diabetes mellitus, neutrophilia, lymphocytopenia, high D-dimer, and increased lymphocyte to monocyte ratio in patients with breast cancer may aggravate the course of COVID-19 disease. These parameters may be predictive for closer follow-up in terms of clinical deterioration of the patients.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2023-02-12
Published 2023-02-15
References
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine 2020;382(18):1708-1720.
Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020;10(6):783-791.
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335-337.
Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncology 2020;21(7): 904–913.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395(10241):1907-1918.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer J Clin 2018;68:394e424.
Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015; 100: 107–13.
CDC. COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343–46.
Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS. Rev Med Virol 2020;30(3):e2107.
Ying H, Deng Q, He B, et al. The prognostic value of preoperative NLR, d-NLR, PLR, and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol (Northwood, Lond, Engl) 2014;31(12):305.
Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR, and PLR inCOVID-19 patients. Int Immunopharmacol 2020;84:106504.
Usul E, Şan İ, Bekgöz B, Şahin A. Role of hematological parameters in COVID-19 patients in the emergency room. Biomark Med 2020;14(13):1207–15.
Peng J, Qi D, Yuan G, et al. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): a multicenter, cross-sectional study. J Clin Lab Anal 2020;34:e23475.
Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun 2017;85:117–25.
Wei J, Wu M, Liu J, et al. Characteristics and outcomes of COVID-19 infection in 45 patients with breast cancer: a multi-center retrospective study in Hubei, China. The Breast 2021; 59:102-109.
Vuagnat P, Frelaut M, Ramtohul T, et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Research 2020; 22(1): 1-10.
Kalinsky K, Accordino MK, Hosi K, et al. Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast cancer research and treatment 2020;182(1):239-242.
Ecin S.M, Gezer D. Evaluation of the relationship between COVID-19 and hyperglycemia. Medicine. 2022; 11(1), 85-9.
Yao Y, Cao J, Wang Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: A case-control study. J Intensive Care 2020; 8(1):1-11.